辛伐他汀对慢性心力衰竭患者心功能及白介素、脑钠肽水平的影响  

Effect of simvastatin on cardiac function and IL-1,BNP levels for the patients with chronic heart failure

作　　者：段丽敏[1] 孙俐俐[1] 王丽娜[1] 张新[1] 

机构地区：[1]大庆油田总医院心内科,黑龙江大庆163001

出　　处：《中国医药导报》2011年第18期88-90,共3页China Medical Herald

摘　　要：目的:观察辛伐他汀对慢性心力衰竭患者心功能及白介素(IL-1)、脑钠肽(BNP)水平的影响。方法:将本院2007年6月～2010年6月住院治疗的76例慢性心力衰竭患者随机分为观察组和对照组各38例,两组均给予常规抗心力衰竭治疗,观察组在常规治疗基础上给予辛伐他汀20 mg,每晚1次,疗程为3个月。治疗前1 d及治疗后12周心脏超声测心功能,包括左室射血分数(LVEF)、左室收缩末内径(LVSD)、左室舒张末内径(LVDD)、左室内径缩短率(FS),并检测血清BNP、IL-1。结果:观察组显效率为65.8%(25/38),总有效率为92.1%(35/38),对照组显效率为44.7%(17/18),总有效率为86.8%(33/38),两组显效率和总有效率分别比较,差异有统计学意义(P<0.05)。观察组治疗前后LVEF、FS、LVDD、LVSD有显著变化[(35.2±4.7)%vs(47.2±6.2)%;(16.1±0.7)%vs(20.5±0.4)%;(60.2±4.6)mm vs(55.3±4.4)mm;(43.5±5.2)mm vs(36.3±4.8)mm,P<0.05],对照组治疗前后LVEF、FS、LVSD、LVDD也有显著变化[34.3±5.1)%vs(42.4±5.6)%;(15.4±0.8)%vs(17.4±0.7)%;(62.6±3.7)mm vs(59.2±5.7)mm;(44.1±4.0)mm vs(40.3±3.9)mm,P<0.05],且治疗后观察组改善明显优于对照组,两组分别比较,差异有统计学意义[47.2±6.2)%vs(42.4±5.6)%;(20.5±0.41)%vs(7.4±0.7)%;(55.3±4.4)mm vs(59.2±5.7)mm,(36.3±4.8)mm vs(40.3±3.9)mm,P<0.05]。观察组和对照组治疗后IL-1、BNP水平较治疗前比较均明显降低,且观察组降低水平优于对照组,两组分别比较,差异有统计学意义(P<0.05)。结论:辛伐他汀治疗慢性心力衰竭疗效确切,可以明显改善患者心的功能,降低IL-1、BNP的水平,值得临床推广应用。Objective： To observe the effect simvastatin on cardiac function and interleukin（IL-1）,brain natriuretic peptide（BNP） levels for the patients with chronic heart failure.Methods： 76 patients with chronic heart failure were randomly divided into two groups respectively 38 cases from June 2007 to June 2010 in our hospital.And the two groups were given conventional therapy,the observation group were given simvastatin 20 mg on the base of conventional therapy,once every night,total 3 months treatment.One day before treatment and 12 weeks after treatment,to test cardiac function with heart ultrasound including left ventricular ejection fraction（LVEF）,left ventricular end systolic diameter（LVSD）,left ventricular end diastolic diameter（LVDD）,left ventricular shortening fraction（FS）,and serum BNP,IL-1.Results： The efficiency of the observation group was 65.8%（25/38） and the total effective rate was 92.1%（35/38）,it was significantly higher than control group（44.7%,86.8%）,P0.05.LVEF,FS,LVSD,LVDD of the observation group were significantly improved after treatment[（35.2±4.7）% vs（47.2±6.2）%;（16.1±0.7）% vs（20.5±0.4）%;（60.2±4.6） mm vs（55.3±4.4） mm;（43.5±5.2） mm vs（36.3±4.8） mm,P0.05],and that of control group improved too[（34.3±5.1）% vs（42.4±5.6）%;（15.4±0.8）% vs（17.4±0.7）%;（62.6±3.7） mm vs（59.2±5.7） mm;（44.1±4.0） mm vs（40.3±3.9） mm,P0.05].And the Improvement of observation group was better than control group [（47.2±6.2）% vs（42.4±5.6）%;（20.5±0.41）% vs（7.4±0.7）%;（55.3±4.4） mm vs（59.2±5.7） mm,（36.3±4.8） mm vs（40.3±3.9） mm,P0.05].IL-1,BNP levels were significantly lower than that before treatment,and reduce level of the observation group was significantly better than the control group（P0.05）.Conclusion： Simvastatin is effective to treat the chronic heart failure,and it can improve cardiac function and reduce IL-1,BNP level,it is worthy of clinical application.

关 键 词：辛伐他汀 慢性心力衰竭 心功能 白介素 脑钠肽 

分 类 号：R541.6[医药卫生—心血管疾病]